Heart, Lung and Circulation
Volume 18, Issue 2 , Pages 118-122 , April 2009

Cost-effectiveness Considerations of Cardiovascular Therapeutics

  • Anthony Keech

      Affiliations

    • NHMRC Clinical Trials Centre and Department of Cardiology, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
    • Corresponding Author InformationCorresponding author.
    • ,
  • John D. Horowitz

      Affiliations

    • Cardiology Unit, Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia

References 

  1. Harvard Centre for Risk Analysis Tables. At www.hcra.harvard.edu.
  2. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358:661–663
  3. Briffa TG, Eckermann SD, Griffiths AD, et al. Cost-effectiveness of cardiac rehabilitation after an acute coronary event: a randomised controlled trial. MJA. 2005;183:450–455
  4. Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet. 2007;370:1552–1559
  5. Unger SA, Robinson MB, Horowitz JD. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust NZ J Med. 1997;27:24–28
  6. ONTARGET Investigators Yusuf S, Teo KK, et al. Telmisartan,ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559
  7. Cannon CP, Nraunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  8. Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomized trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  9. Delaney JA, Daskalopoulou SS, Suissa S. Traditional versus marginal structural models to estimate the effectiveness of beta-blocker use on mortality after myocardial infarction. Pharmacoepidemiol Drug Saf. 2008;[Epub]
  10. Flather MD, Yusuf S, Keber L, et al. Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575–1581
  11. Baigent C, Keech A, Kearney PM, et al. On behalf of the Choelsterol Treatment Trialists’ Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2006;1267–1278
  12. Yusuf S, Zhao F, Chrolavicius S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:492–502
  13. Prevention of cardiovascular events and death with pravastatin inpatients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–1357
  14. Tonkin AM, Eckermann S, White H, et al. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndrome aged 65 to 74 years compared to younger patients: results from the LIPID study. Am Heart J. 2006;151:1305–1312

PII: S1443-9506(08)00953-0

doi: 10.1016/j.hlc.2008.11.006

Heart, Lung and Circulation
Volume 18, Issue 2 , Pages 118-122 , April 2009

Article Tools